These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7612408)

  • 1. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.
    Vallance DK; Lynch JP; McCune WJ
    Curr Opin Rheumatol; 1995 May; 7(3):174-82. PubMed ID: 7612408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclophosphamide for scleroderma lung disease.
    Martinez FJ; McCune WJ
    N Engl J Med; 2006 Jun; 354(25):2707-9. PubMed ID: 16790705
    [No Abstract]   [Full Text] [Related]  

  • 3. Cyclophosphamide versus placebo in scleroderma lung disease.
    Tashkin DP; Elashoff R; Clements PJ; Goldin J; Roth MD; Furst DE; Arriola E; Silver R; Strange C; Bolster M; Seibold JR; Riley DJ; Hsu VM; Varga J; Schraufnagel DE; Theodore A; Simms R; Wise R; Wigley F; White B; Steen V; Read C; Mayes M; Parsley E; Mubarak K; Connolly MK; Golden J; Olman M; Fessler B; Rothfield N; Metersky M;
    N Engl J Med; 2006 Jun; 354(25):2655-66. PubMed ID: 16790698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum LL-37 levels correlate with the efficacy of i.v. cyclophosphamide pulse for skin sclerosis and interstitial lung disease in systemic sclerosis.
    Takahashi T; Asano Y; Taniguchi T; Yoshizaki A; Sato S
    J Dermatol; 2017 Apr; 44(4):468-469. PubMed ID: 28378437
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclophosphamide in scleroderma lung disease.
    Sullivan KM; McSweeney PA; Nash RA
    N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.
    Nannini C; West CP; Erwin PJ; Matteson EL
    Arthritis Res Ther; 2008; 10(5):R124. PubMed ID: 18937831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide in scleroderma lung disease.
    Andreu JL; Silva L
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700
    [No Abstract]   [Full Text] [Related]  

  • 8. Cyclophosphamide in scleroderma lung disease.
    Kuschner WG
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16971726
    [No Abstract]   [Full Text] [Related]  

  • 9. Unusual association of systemic sclerosis and ankylosing spondylitis.
    Soledade CS; Sampaio-Barros PD; Samara AM; Marques-Neto JF
    Clin Rheumatol; 2005 Nov; 24(6):652-4. PubMed ID: 15338450
    [No Abstract]   [Full Text] [Related]  

  • 10. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.
    Strange C; Bolster MB; Roth MD; Silver RM; Theodore A; Goldin J; Clements P; Chung J; Elashoff RM; Suh R; Smith EA; Furst DE; Tashkin DP;
    Am J Respir Crit Care Med; 2008 Jan; 177(1):91-8. PubMed ID: 17901414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease.
    Numajiri H; Yoshizaki A; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Sumida H; Asano Y; Kazoe Y; Mawatari K; Kitamori T; Sato S
    J Dermatol; 2018 Oct; 45(10):1221-1224. PubMed ID: 30051925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
    Fathi N; Furst DE; Clements PJ
    Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
    Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
    Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A case of systemic sclerosis associated with interstitial pneumonia with various autoantibodies: improvement by intravenous cyclophosphamide therapy].
    Ishiyama K; Suwa A; Ohta S; Moriguchi M; Suzuki T; Miyachi K; Hara M; Kashiwazaki S
    Nihon Rinsho Meneki Gakkai Kaishi; 1996 Oct; 19(5):512-8. PubMed ID: 8952320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of mycophenolate associated with methotrexate as a maintenance treatment for systemic sclerosis-associated interstitial lung disease].
    Gonzalez-Nieto JA; Martin-Suarez IJ; Gil-Muñoz FL
    Arch Bronconeumol; 2011 Nov; 47(11):575. PubMed ID: 21821334
    [No Abstract]   [Full Text] [Related]  

  • 16. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
    Jain S; Shahane A; Derk CT
    Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide pulse therapy for rapidly progressive interstitial pneumonia in dermatomyositis. A new possibility for rescue?
    Takizawa H; Ito K
    Intern Med; 1997 Jul; 36(7):448-9. PubMed ID: 9240490
    [No Abstract]   [Full Text] [Related]  

  • 18. An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.
    McMahan ZH; Volkmann ER
    Expert Opin Pharmacother; 2020 Nov; 21(16):2041-2056. PubMed ID: 32674612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapidly progressive interstitial lung disease associated with dermatomyositis responding to intravenous cyclophosphamide pulse therapy.
    Shinohara T; Hidaka T; Matsuki Y; Ishizuka T; Takamizawa M; Kawakami M; Kikuma H; Suzuki K; Nakamura H
    Intern Med; 1997 Jul; 36(7):519-23. PubMed ID: 9240505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.